The Enforcement Landscape
State boards of pharmacy conduct routine inspections, and a documented deficiency can lead to a corrective action plan or a follow-up inspection. Critical deficiencies are those requiring corrective action plans or follow-up inspections.
The DEA's Diversion Control Division takes pharmacy-specific administrative actions, including immediate suspension orders that can shut a pharmacy down quickly.
PBMs also audit pharmacy locations, and they issue recoupment demands when documentation falls short.
Five Inspection Deficiencies That Come Up Repeatedly
Five deficiency categories come up repeatedly in pharmacy inspections:
1. Expired or Incomplete Training Records
Staff training records - HIPAA, FWA, OSHA, controlled substance handling - are either missing, expired, or incomplete. Inspectors consistently report that pharmacies can produce evidence of initial training at hire but cannot demonstrate ongoing annual recertification.
2. Documentation and Recordkeeping Gaps
This covers a broad range: missing prescription hardcopies, incomplete dispensing logs, absent temperature monitoring records, and gaps in controlled substance inventories. The common thread is that the pharmacy knows what records they need to keep but has not built a system to verify completeness.
3. Policy and Procedure Manual Deficiencies
Policies that have not been reviewed or updated in years. Missing required policies (many states now mandate specific policy topics). Policies that do not match actual pharmacy operations. A P&P manual is not a decoration - it is an operational document that regulators expect to reflect reality.
4. Facility and Signage Issues
Missing or outdated regulatory postings, improper controlled substance storage, inadequate security measures, and expired fire safety equipment. These are visual deficiencies that inspectors identify within minutes of entering a pharmacy.
5. Controlled Substance Discrepancies
Inventory counts that do not reconcile, missing DEA 222 forms, gaps in the perpetual inventory for Schedule II drugs, and failure to report losses or thefts within required timeframes. DEA inspectors focus heavily on this area, and discrepancies here escalate quickly from administrative findings to criminal referrals.
Penalty Severity by Category
Not all deficiencies carry equal consequences:
Controlled substance violations can carry the steepest penalties. Immediate suspension orders - which effectively shut down a pharmacy overnight - are among the most severe outcomes.
HIPAA breaches resulting from inspection-identified gaps can lead to OCR settlements. The range is enormous, from small-scale violations to systemic failures.
State board penalties are more modest in dollar terms but carry operational consequences. License suspensions, mandatory corrective action plans, and increased inspection frequency all impose costs that go beyond fines.
PBM recoupments hit the bottom line directly. Pharmacies with organized documentation are in a far better position on appeal than those scrambling to assemble records.
Regional Differences Worth Knowing
Enforcement activity is not uniform across the country. Inspection programs, required policies, and enforcement priorities vary by state, so check the rules and current priorities of your own state board of pharmacy.
What This Means for Your Pharmacy
The pattern points to a clear conclusion: the cost of proactive compliance infrastructure is a fraction of the cost of a single enforcement action. A pharmacy that invests in systematic tracking of training records, documentation, policies, and controlled substance inventories is not just avoiding penalties - it is building operational resilience.
The pharmacies that consistently pass inspections share common characteristics. They have systems rather than spreadsheets. They monitor continuously rather than crambling before inspections. They treat compliance as a daily operational function rather than an annual event.
Whether you build that system internally or work with a compliance partner, the logic is straightforward. A single DEA fine or PBM recoupment can far exceed what proactive compliance infrastructure costs. The return on investment is not even close.
Looking Ahead: 2026 Predictions
Based on current trends, we expect:
- State board inspection frequency to increase, driven by expanded funding and legislative mandates
- DEA to continue prioritizing retail pharmacy enforcement, particularly around controlled substance monitoring and ARCOS reporting
- PBM audit activity to increase in scope, with auditors looking at broader claim populations rather than random samples
- CMS to expand Medicare Part D audit programs, particularly targeting specialty and compound pharmacies
- More states to adopt mandatory compliance program requirements for retail pharmacies
The trend line is unmistakable: regulatory expectations are rising, enforcement is getting more aggressive, and the pharmacies that prepare systematically are the ones that survive.



